Overview

A Study to Assess the Safety and Effectiveness of SJP-0035 for the Treatment of Patients With Dry Eye Disease

Status:
Completed
Trial end date:
2019-03-15
Target enrollment:
Participant gender:
Summary
A double-masked, randomized, multi-center, placebo-controlled, parallel-group study in adult patients with Dry Eye Disease (DED). Patients will be randomly assigned to receive either SJP-0035 0.001% or placebo
Phase:
Phase 3
Details
Lead Sponsor:
Senju Pharmaceutical Co., Ltd.
Treatments:
Ophthalmic Solutions
Pharmaceutical Solutions